Results 111 to 120 of about 93,913 (298)

Development and Validation of Chromatographic and Spectrophotometric Methods for the Quantitation of Rufinamide in Pharmaceutical Preparations. [PDF]

Turk J Pharm Sci, 2022
Rahman H, Haque SM.
europepmc   +1 more source

Brainstem and Cerebellar Volume Loss and Associated Clinical Features in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Progressive Supranuclear Palsy (PSP) is a neurodegenerative ‘tauopathy’ with predominating pathology in the basal ganglia and midbrain. Caudal tau spread frequently implicates the cerebellum; however, the pattern of atrophy remains equivocal.
Chloe Spiegel, Timothy P. Siejka, Cassandra Marotta, Josh J. Y. Lee, Kelly Bertram, Terence J. O'Brien, Meng Law, Lucy Vivash, Ian H. Harding   +8 more
wiley   +1 more source

PENEGAKAN HUKUM PADA TINGKAT PENYIDIKAN TERHADAP PELAKU TINDAK PIDANA PENGEDARAN SEDIAAN FARMASI TANPA IZIN DI KOTA SOLOK

Unes Journal of Swara Justisia, 2019
Article 197 Law number 36 of 2009 concerning Health stipulates that "every person who intentionally produces or distributes pharmaceutical preparations and / or medical devices that do not have a distribution permit is given criminal sanctions and fines"
Defrianto Defrianto, Wirna Rosmely
doaj  

Washed microbiota transplantation: candidates for a novel strategy for ameliorating autism spectrum disorder

Frontiers in Microbiology
Autism Spectrum Disorder (ASD) is a severe neurodevelopmental disorder with an increasing global incidence, imposing substantial burdens on both society and affected families.
Shuo Feng, Shuo Feng, Jiangyan Wang, Jiangyan Wang, Xinyu Si, Xinyu Si, Shenghua Lu, Shenghua Lu, Caimei Lu, Caimei Lu, Zheng Gao, Zheng Gao, Juan Yang, Juan Yang, Jiali Wu, Xingxiang He, Xingxiang He, Lei Wu, Lei Wu   +18 more
doaj   +1 more source

A simple and fast flow injection amperometry for the determination of methimazole in pharmaceutical preparations using an unmodified boron-doped diamond electrode. [PDF]

ADMET DMPK, 2023
Meoipun A, Kaewjua K, Chailapakul O, Siangproh W.   +3 more
europepmc   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Advanced Analytical Approach Based on Combination of FT-IR and Chemometrics for Quality Control of Pharmaceutical Preparations. [PDF]

Pharmaceuticals (Basel), 2022
Foschi M, Marziale M, Biancolillo A.
europepmc   +1 more source

Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, EarlyView.
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations. [PDF]

Chin Med, 2021
Luo H, Chen H, Liu C, Zhang S, Vong CT, Tan D, Dai Y, Wang Y, Chen S.   +8 more
europepmc   +1 more source

Heterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes

Arthritis Care &Research, EarlyView.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source